Current Advances in Studying Clinically Relevant Transporters of the Solute Carrier (SLC) Family by Connecting Computational Modeling and Data Science

Organic anion and cation transporting proteins (OATs, OATPs, and OCTs), as well as the Multidrug and Toxin Extrusion (MATE) transporters of the Solute Carrier (SLC) family are playing a pivotal role in the discovery and development of new drugs due to their involvement in drug disposition, drug-drug interactions, adverse drug effects and related toxicity. Computational methods to understand and predict clinically relevant transporter interactions can provide useful guidance at early stages in drug discovery and design, especially if they include contemporary data science approaches. In this review, we summarize the current state-of-the-art of computational approaches for exploring ligand interactions and selectivity for these drug (uptake) transporters. The computational methods discussed here by highlighting interesting examples from the current literature are ranging from semiautomatic data mining and integration, to ligand-based methods (such as quantitative structure-activity relationships, and combinatorial pharmacophore modeling), and finally structure-based methods (such as comparative modeling, molecular docking, and molecular dynamics simulations). We are focusing on promising computational techniques such as fold-recognition methods, proteochemometric modeling or techniques for enhanced sampling of protein conformations used in the context of these ADMET-relevant SLC transporters with a special focus on methods useful for studying ligand selectivity.

[1]  P. Barton,et al.  Application of an in vitro OAT assay in drug design and optimization of renal clearance , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  S M Swanson,et al.  Molecular modelling and drug design. , 2000, Pharmacology & therapeutics.

[3]  A. Sali,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[4]  So Iwata,et al.  Rationalizing α‐helical membrane protein crystallization , 2008, Protein science : a publication of the Protein Society.

[5]  Sean Ekins,et al.  Molecular Determinants of Ligand Selectivity for the Human Multidrug and Toxin Extruder Proteins MATE1 and MATE2-K , 2012, Journal of Pharmacology and Experimental Therapeutics.

[6]  Thierry Langer,et al.  High-throughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening , 2007, J. Comput. Aided Mol. Des..

[7]  Yang Zhang,et al.  Scoring function for automated assessment of protein structure template quality , 2004, Proteins.

[8]  B. Hagenbuch,et al.  Ligand‐dependent modulation of hOCT1 transport reveals discrete ligand binding sites within the substrate translocation channel , 2018, Biochemical pharmacology.

[9]  Thorsten Meinl,et al.  KNIME - the Konstanz information miner: version 2.0 and beyond , 2009, SKDD.

[10]  I. Tsigelny,et al.  Conformational Changes of the Multispecific Transporter Organic Anion Transporter 1 (OAT1/SLC22A6) Suggests a Molecular Mechanism for Initial Stages of Drug and Metabolite Transport , 2011, Cell Biochemistry and Biophysics.

[11]  Y. Kanai,et al.  Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. , 1999, American journal of physiology. Renal physiology.

[12]  J. E. Rouck,et al.  Recent advances in nanodisc technology for membrane protein studies (2012–2017) , 2017, FEBS letters.

[13]  H. Kusuhara,et al.  Impact of Experimental Conditions on the Evaluation of Interactions between Multidrug and Toxin Extrusion Proteins and Candidate Drugs , 2016, Drug Metabolism and Disposition.

[14]  Kalyan C. Tirupula,et al.  Identification of motions in membrane proteins by elastic network models and their experimental validation. , 2012, Methods in molecular biology.

[15]  C. Drenberg,et al.  OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. , 2017, Cancer research.

[16]  S. Ekins,et al.  Molecular Determinants of Substrate/Inhibitor Binding to the Human and Rabbit Renal Organic Cation Transporters hOCT2 and rbOCT2 , 2005, Molecular Pharmacology.

[17]  Yongxue Sun,et al.  Identification of Multiple Binding Sites for Substrate Transport in Bovine Organic Anion Transporting Polypeptide 1a2 , 2013, Drug Metabolism and Disposition.

[18]  Zhijun Li,et al.  Developing a high-quality scoring function for membrane protein structures based on specific inter-residue interactions , 2012, Journal of Computer-Aided Molecular Design.

[19]  A. Vulpetti,et al.  Comparability of Mixed IC50 Data – A Statistical Analysis , 2013, PloS one.

[20]  Pär Matsson,et al.  Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. , 2011, Journal of medicinal chemistry.

[21]  Andrej Sali,et al.  Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. , 2013, Journal of medicinal chemistry.

[22]  S. Wright,et al.  Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[23]  Ivet Bahar,et al.  On the functional significance of soft modes predicted by coarse-grained models for membrane proteins , 2010, The Journal of general physiology.

[24]  David T. Jones,et al.  pGenTHREADER and pDomTHREADER: new methods for improved protein fold recognition and superfamily discrimination , 2009, Bioinform..

[25]  S. Ekins,et al.  Comparative Pharmacophore Modeling of Organic Anion Transporting Polypeptides: A Meta-Analysis of Rat Oatp1a1 and Human OATP1B1 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[26]  S. Iwata,et al.  Benchmarking Membrane Protein Detergent Stability for Improving Throughput of High-Resolution X-ray Structures , 2011, Structure.

[27]  Nan Li,et al.  Identification of Amino Acids Essential for Estrone-3-Sulfate Transport within Transmembrane Domain 2 of Organic Anion Transporting Polypeptide 1B1 , 2012, PloS one.

[28]  V. Ganapathy,et al.  cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. , 1998, Biochemical and biophysical research communications.

[29]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[30]  G. V. van Westen,et al.  Structure-Based Identification of OATP1B1/3 Inhibitors , 2013, Molecular Pharmacology.

[31]  M. Sansom,et al.  Conformational change in an MFS protein: MD simulations of LacY. , 2007, Structure.

[32]  D. Slotboom,et al.  Revolutionizing membrane protein overexpression in bacteria , 2009, Microbial biotechnology.

[33]  P. Neuvonen,et al.  Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance , 2006, Clinical pharmacology and therapeutics.

[34]  Chung F. Wong,et al.  Flexible receptor docking for drug discovery , 2015, Expert opinion on drug discovery.

[35]  P. Zielenkiewicz,et al.  Why similar protein sequences encode similar three-dimensional structures? , 2010 .

[36]  Richard A. Lewis,et al.  Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. , 2004, Journal of medicinal chemistry.

[37]  K. Maeda,et al.  Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[38]  K. Giacomini,et al.  The UCSF‐FDA TransPortal: A Public Drug Transporter Database , 2012, Clinical pharmacology and therapeutics.

[39]  Y. Kanai,et al.  Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. , 2001, Molecular pharmacology.

[40]  A. Vulpetti,et al.  The experimental uncertainty of heterogeneous public K(i) data. , 2012, Journal of medicinal chemistry.

[41]  Sheng-Yong Yang,et al.  Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.

[42]  A. Sali,et al.  Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1). , 2017, Journal of medicinal chemistry.

[43]  Cheng Luo,et al.  Combinatorial Pharmacophore Modeling of Multidrug and Toxin Extrusion Transporter 1 Inhibitors: a Theoretical Perspective for Understanding Multiple Inhibitory Mechanisms , 2015, Scientific Reports.

[44]  Thomas Lengauer,et al.  Computational methods for biomolecular docking. , 1996, Current opinion in structural biology.

[45]  G Klebe,et al.  Docking ligands onto binding site representations derived from proteins built by homology modelling. , 2001, Journal of molecular biology.

[46]  Christel A. S. Bergström,et al.  Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. , 2008, Journal of medicinal chemistry.

[47]  S. Ravichandran,et al.  Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1) , 2007, British journal of pharmacology.

[48]  B. Hagenbuch,et al.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies , 2012, British journal of pharmacology.

[49]  Gerard J. P. van Westen,et al.  Significantly Improved HIV Inhibitor Efficacy Prediction Employing Proteochemometric Models Generated From Antivirogram Data , 2013, PLoS Comput. Biol..

[50]  O. Ogawa,et al.  Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.

[51]  John J. Irwin,et al.  Community benchmarks for virtual screening , 2008, J. Comput. Aided Mol. Des..

[52]  Flavio Ballante,et al.  Protein-Ligand Docking in Drug Design: Performance Assessment and Binding-Pose Selection. , 2018, Methods in molecular biology.

[53]  Arunachalam Jothi Principles, challenges and advances in ab initio protein structure prediction. , 2012, Protein and peptide letters.

[54]  Min-Sun Park,et al.  Proton-coupled sugar transport in the prototypical major facilitator superfamily protein XylE , 2014, Nature Communications.

[55]  Alžběta Türková,et al.  Integrative Data Mining, Scaffold Analysis, and Sequential Binary Classification Models for Exploring Ligand Profiles of Hepatic Organic Anion Transporting Polypeptides , 2018, J. Chem. Inf. Model..

[56]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[57]  Osamu Ogawa,et al.  Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. , 2007, Biochemical pharmacology.

[58]  K. Mizuguchi,et al.  Organic Anion Transporting Polypeptides of the OATP/SLCO Superfamily: Identification of New Members in Nonmammalian Species, Comparative Modeling and a Potential Transport Mode , 2006, The Journal of Membrane Biology.

[59]  Pedro J Ballester,et al.  Machine‐learning scoring functions to improve structure‐based binding affinity prediction and virtual screening , 2015, Wiley interdisciplinary reviews. Computational molecular science.

[60]  G Vriend,et al.  Completion and refinement of 3‐D homology models with restricted molecular dynamics: Application to targets 47, 58, and 111 in the CASP modeling competition and posterior analysis , 2002, Proteins.

[61]  Bernard R Brooks,et al.  Probing the periplasmic-open state of lactose permease in response to sugar binding and proton translocation. , 2010, Journal of molecular biology.

[62]  Yang Zhang,et al.  I-TASSER server for protein 3D structure prediction , 2008, BMC Bioinformatics.

[63]  Barbara Zdrazil,et al.  Selectivity profiling of BCRP versus P-gp inhibition: from automated collection of polypharmacology data to multi-label learning , 2016, Journal of Cheminformatics.

[64]  Sean Ekins,et al.  Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. , 2010, Molecular pharmaceutics.

[65]  Y. Sugita,et al.  Molecular dynamics simulations of biological membranes and membrane proteins using enhanced conformational sampling algorithms. , 2016, Biochimica et biophysica acta.

[66]  Thomas L. Rodgers,et al.  Modulation of Global Low-Frequency Motions Underlies Allosteric Regulation: Demonstration in CRP/FNR Family Transcription Factors , 2013, PLoS biology.

[67]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[68]  Stefan Brenner,et al.  Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models , 2015, Molecular pharmaceutics.

[69]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands , 2013, Nucleic Acids Res..

[70]  Mei Hong,et al.  Amino Acid Residues in the Putative Transmembrane Domain 11 of Human Organic Anion Transporting Polypeptide 1B1 Dictate Transporter Substrate Binding, Stability, and Trafficking. , 2015, Molecular pharmaceutics.

[71]  P. Dawson,et al.  Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine , 2002, Clinical pharmacology and therapeutics.

[72]  Gerard J. P. van Westen,et al.  Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets , 2011 .

[73]  Keehyoung Joo,et al.  Improving physical realism, stereochemistry, and side‐chain accuracy in homology modeling: Four approaches that performed well in CASP8 , 2009, Proteins.

[74]  Cheng Luo,et al.  Combinatorial pharmacophore modeling of organic cation transporter 2 (OCT2) inhibitors: insights into multiple inhibitory mechanisms. , 2013, Molecular pharmaceutics.

[75]  T. Lundstedt,et al.  Proteochemometrics modeling of the interaction of amine G-protein coupled receptors with a diverse set of ligands. , 2002, Molecular pharmacology.

[76]  Avner Schlessinger,et al.  Molecular modeling and ligand docking for solute carrier (SLC) transporters. , 2013, Current topics in medicinal chemistry.

[77]  James M. Stevenson and,et al.  Pipeline Pilot 2.1 By Scitegic, 9665 Chesapeake Drive, Suite 401, San Diego, CA 92123-1365. www.scitegic.com. See Web Site for Pricing Information , 2003 .

[78]  J. Venhorst,et al.  Generation of Bayesian prediction models for OATP-mediated drug-drug interactions based on inhibition screen of OATP1B1, OATP1B1∗15 and OATP1B3. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[79]  Philip C Biggin,et al.  Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations , 2016, Journal of the American Chemical Society.

[80]  David C. Young,et al.  Computational Chemistry: A Practical Guide for Applying Techniques to Real World Problems , 2001 .

[81]  Richard Svensson,et al.  In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions , 2011, Pharmaceutical Research.

[82]  Nashville Tennessee,et al.  Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2) , 2005, Journal of Biological Chemistry.

[83]  C. Tate,et al.  Engineering G protein-coupled receptors to facilitate their structure determination. , 2009, Current opinion in structural biology.

[84]  M. Niemi,et al.  Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.

[85]  P. Dutta,et al.  Exploration of conformational changes in lactose permease upon sugar binding and proton transfer through coarse‐grained simulations , 2017, Proteins.

[86]  N. Dokholyan,et al.  Predicting the functional consequences of non-synonymous single nucleotide polymorphisms in IL8 gene , 2017, Scientific Reports.

[87]  J. B. Pritchard,et al.  A Three-dimensional Model of Human Organic Anion Transporter 1 , 2006, Journal of Biological Chemistry.

[88]  The Development, Characterization, and Application of an OATP1B1 Inhibition Assay in Drug Discovery , 2012, Drug Metabolism and Disposition.

[89]  B. Sokouti,et al.  Quantitative Structure – Activity Relationship: A Practical Approach , 2018 .

[90]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[91]  S. Ekins,et al.  Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. , 2003, Molecular pharmacology.

[92]  H. Glaeser,et al.  Functional and Structural Relevance of Conserved Positively Charged Lysine Residues in Organic Anion Transporting Polypeptide 1B3 , 2011, Molecular Pharmacology.

[93]  Hans-Joachim Böhm,et al.  Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs , 1998, J. Comput. Aided Mol. Des..

[94]  A. Sali,et al.  Computational Discovery and Experimental Validation of Inhibitors of the Human Intestinal Transporter OATP2B1 , 2017, J. Chem. Inf. Model..

[95]  Ulf Norinder,et al.  Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions , 2012, Journal of medicinal chemistry.

[96]  Michael Feig,et al.  Implicit membrane models for membrane protein simulation. , 2008, Methods in molecular biology.

[97]  H. Hansen,et al.  Screening of OATP1B1/3 and OCT1 inhibitors in cryopreserved hepatocytes in suspension. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[98]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[99]  P. Hrelia,et al.  Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. , 2013, Pharmacological research.

[100]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[101]  T. Nakanishi,et al.  Molecular localization and characterization of multiple binding sites of organic anion transporting polypeptide 2B1 (OATP2B1) as the mechanism for substrate and modulator dependent drug–drug interaction , 2016 .

[102]  M. Rarey Protein–Ligand Docking in Drug Design , 2004 .

[103]  Elizabeth Yuriev,et al.  Free Energy Methods in Drug Design: Prospects of "Alchemical Perturbation" in Medicinal Chemistry. , 2017, Journal of medicinal chemistry.

[104]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[105]  Shan Chang,et al.  Allosteric and transport behavior analyses of a fucose transporter with network models , 2011 .

[106]  H. Glaeser,et al.  Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3 , 2010, British journal of pharmacology.

[107]  A. Sali,et al.  Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.

[108]  A. Schlessinger,et al.  SLC Transporters: Structure, Function, and Drug Discovery. , 2016, MedChemComm.

[109]  F. Lang,et al.  Cloning and characterization of two human polyspecific organic cation transporters. , 1997, DNA and cell biology.

[110]  V. Ladizhansky,et al.  Applications of solid-state NMR to membrane proteins. , 2017, Biochimica et Biophysica Acta - Proteins and Proteomics.

[111]  S. Newstead,et al.  Membrane Protein Crystallisation: Current Trends and Future Perspectives , 2016, Advances in experimental medicine and biology.

[112]  C. Gui,et al.  Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport. , 2008, Biochemistry.

[113]  Joseph L. Baker,et al.  Twelve Transmembrane Helices Form the Functional Core of Mammalian MATE1 (Multidrug and Toxin Extruder 1) Protein* , 2012, The Journal of Biological Chemistry.

[114]  P. Meier,et al.  Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. , 2001, Gastroenterology.

[115]  Carlos J. Camacho,et al.  Choosing the Optimal Rigid Receptor for Docking and Scoring in the CSAR 2013/2014 Experiment , 2016, J. Chem. Inf. Model..

[116]  Brian K Shoichet,et al.  Testing a flexible-receptor docking algorithm in a model binding site. , 2004, Journal of molecular biology.

[117]  Jitender Verma,et al.  3D-QSAR in drug design--a review. , 2010, Current topics in medicinal chemistry.

[118]  H. Kusuhara,et al.  Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices , 2007, Journal of Pharmacology and Experimental Therapeutics.

[119]  A. Schlessinger,et al.  Molecular Modeling of Drug–Transporter Interactions—An International Transporter Consortium Perspective , 2018, Clinical pharmacology and therapeutics.

[120]  Yang Zhang,et al.  Protein Structure and Function Prediction Using I‐TASSER , 2015, Current protocols in bioinformatics.

[121]  D. Kell,et al.  The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. , 2013, Drug discovery today.

[122]  P. Swaan,et al.  Multi-level Analysis of Organic Anion Transporters 1, 3, and 6 Reveals Major Differences in Structural Determinants of Antiviral Discrimination* , 2008, Journal of Biological Chemistry.

[123]  Baofeng Zhang,et al.  Large scale free energy calculations for blind predictions of protein–ligand binding: the D3R Grand Challenge 2015 , 2016, Journal of Computer-Aided Molecular Design.

[124]  J. Bajorath,et al.  Recent Advances in Scaffold Hopping. , 2017, Journal of medicinal chemistry.

[125]  Prabha Garg,et al.  Selective Fusion of Heterogeneous Classifiers for Predicting Substrates of Membrane Transporters , 2017, J. Chem. Inf. Model..

[126]  I. Muegge PMF scoring revisited. , 2006, Journal of medicinal chemistry.

[127]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[128]  Ken-ichi Inui,et al.  Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney , 2013, The AAPS Journal.

[129]  D A Agard,et al.  Modeling side-chain conformation for homologous proteins using an energy-based rotamer search. , 1993, Journal of molecular biology.

[130]  M. Scalise,et al.  OCTN Cation Transporters in Health and Disease , 2013, Journal of biomolecular screening.

[131]  R. Kim,et al.  Naringin is a Major and Selective Clinical Inhibitor of Organic Anion‐Transporting Polypeptide 1A2 (OATP1A2) in Grapefruit Juice , 2007, Clinical pharmacology and therapeutics.

[132]  Andrzej Kolinski,et al.  Modeling of loops in proteins: a multi-method approach , 2010, BMC Structural Biology.

[133]  Bruno Stieger,et al.  Organic anion-transporting polypeptides. , 2014, Current topics in membranes.

[134]  Sean Ekins,et al.  Novel Inhibitors of Human Organic Cation/Carnitine Transporter (hOCTN2) via Computational Modeling and In Vitro Testing , 2009, Pharmaceutical Research.

[135]  R. Fredriksson,et al.  Classification Systems of Secondary Active Transporters. , 2017, Trends in pharmacological sciences.

[136]  Björn Wallner,et al.  Model quality assessment for membrane proteins , 2010, Bioinform..

[137]  Andreas Bender,et al.  Metrabase: a cheminformatics and bioinformatics database for small molecule transporter data analysis and (Q)SAR modeling , 2015, Journal of Cheminformatics.

[138]  J. Valverde Molecular Modelling: Principles and Applications , 2001 .

[139]  Floriane Montanari,et al.  BCRP Inhibition: from Data Collection to Ligand‐Based Modeling , 2014, Molecular informatics.

[140]  Rajender Kumar,et al.  Structural modeling of human organic cation transporters , 2017, Comput. Biol. Chem..

[141]  A. Enomoto,et al.  Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. , 2002, The Journal of pharmacology and experimental therapeutics.

[142]  Z. Luthey-Schulten,et al.  Ab initio protein structure prediction. , 2002, Current opinion in structural biology.

[143]  András Fiser,et al.  ModLoop: automated modeling of loops in protein structures , 2003, Bioinform..

[144]  J. König,et al.  Double‐transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations , 2011, British journal of pharmacology.